Answers are grounded in this paper and cite their sources.
Objectives: The objectives of this review were to systematically evaluate the literature on intrawound vancomycin in adult tibia fractures, comparing efficacy in preventing SSIs/FRIs between standard-risk and high-risk fracture cohorts. Material and Methods: PubMed/MEDLINE, Cochrane CENTRAL, and Embase (via Ovid) were searched from inception to August 2026, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) guidelines. The review was registered on PROSPERO (CRD420261473079). Comparative studies of intrawound vancomycin versus standard care in tibial fracture fixation were included, grouped by risk categoryand synthesized qualitatively. Results: 5 comparative studies comprising 1,815 patients (4 high-risk, n = 1,356; 1 standard-risk, n = 459) met inclusion criteria. High-risk studies consistently reported reduced gram-positive SSIs/FRIs with intrawound vancomycin use, with negligible effect on gram-negative organisms. The single included standard-risk study reported a similar trend, but rested solely on a single, non-randomized, single-center study. Conclusion: Intrawound vancomycin powder is associated with a reduction in gram-positive deep infection following tibial fracture fixation in both high-risk and standard-risk cohorts, with no discernible effect on gram-negative infections in either cohort. However, the evidence base for standard-risk application is much narrower, and any interpretations of evidence relating to this cohort should be done cautiously. This review highlights the need for suitably powered research investigating the use of intrawound vancomycin in standard-risk tibial fracture patients.
No takes yet. Share an insight, caveat, or question.
Hussain et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: